← Eichor
Study identifier: NCT07675109 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Optimizing Extended-Duration (XD-) TOMAC Therapy for Restless Legs Syndrome (RLS)

Condition: Restless Legs Syndrome (RLS)  ·  Sponsor: Noctrix Health, Inc.

PhaseNA
Planned participants20
Who can joinAll sexes, 21 Years to no upper limit
Healthy volunteersNo

About this study

This study assesses the tolerability, safety, and impact of an investigational medical device on restless legs syndrome symptoms. The IRB has established that the investigational device is non-significant risk.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Research Coordinator  ·  415-531-1578  ·  clinicalcoordinator@noctrixhealth.com

Always discuss trial participation with your own doctor first.

Locations (1)

Noctrix Health HeadquartersPleasanton, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07675109